Eduardo Tolosa
Neurology · 2005–2022
A researcher in the Science corpus: 13 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Neurology — 123 citations into it
- Complementary and alternative medicine — 5 citations into it
Whom Eduardo Tolosa trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from Eduardo Tolosa's perspective
Ordered by how strongly the researchers Eduardo Tolosa trusts endorse each paper. Same corpus, a different order for every researcher.
- Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease (Neurology)
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. (The Lancet)
- MDS clinical diagnostic criteria for Parkinson's disease (Movement Disorders)
- The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment (Journal of The American Geriatrics Society)
- The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years (Movement Disorders)
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results (Movement Disorders)
- Glial reactions in Parkinson's disease (Movement Disorders)
- Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders (Acta Neuropathologica)
- Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. (Science)
- A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. (American Journal of Human Genetics)
Their papers
- The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy (2022) — 689 citations
- Challenges in the diagnosis of Parkinson’s disease (2021) — 1,398 citations
- Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-genome wide association study (2019) — 1,651 citations
- The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort (2018) — 595 citations
- Past, Present, and Future of Parkinson’s Disease: A Special Essay on the 200th Anniversary of the Shaking Palsy (2017) — 734 citations
- Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. (2013) — 680 citations
- Criteria for the diagnosis of corticobasal degeneration (2013) — 1,623 citations
- Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study (2008) — 1,476 citations
- The role of DAT-SPECT in movement disorders (2008) — 314 citations
- Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force (2007) — 1,057 citations
- Clinical diagnostic criteria for dementia associated with Parkinson's disease (2007) — 2,957 citations
- Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. (2006) — 905 citations
- Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. (2005) — 598 citations